Genentech and Novartis have teamed up with Food Allergy Research & Education (FARE) to enhance the safety of children with ...

Novartis commits $7.5 million to the "Blitz the Barriers" campaign, aiming to raise awareness and encourage early testing for ...

The U.S. Department of Justice has filed an appeals court brief supporting the right of Medicare officials to negotiate ...

Novartis has committed $7.5 million to an initiative aiming to save 100,000 lives by 2035. The money will launch Zero ...

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...

One of Monte Rosa's main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders.

Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...

To learn more about food allergies or access FARE resources, please visit foodallergy.org.

Novartis is one of the world's top pharmaceutical companies, and along with neighbours Roche, the mainstay of Switzerland's centuries-long contribution to new medicines. Headquartered in Basel ...

Vincent Gaynor remembers, almost to the minute, when he realized his part in birthing the breakthrough gene therapy Zolgensma ...

As we approach the first anniversary of omalizumab’s approval for food allergy, its use is “definitely going to grow,” Robert ...